Review and Interpretation of the 2021 American Society of Clinical Oncology (ASCO) Meeting

Review and Interpretation of the American Society of Clinical Oncology (ASCO) Meeting 2021 is organized by Indiana University School of Medicine (IUSM).

Target Audience:
Specialties - Hematology and Oncology, Nursing, Pharmacy

Accreditation:
Nurses
Indiana University School of Medicine designates this activity for a maximum of 5.75 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists
Indiana University School of Medicine designates this activity for 5.75 ACPE contact hours. Pharmacists should only claim credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

Physicians
Indiana University School of Medicine designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Overview:
This program will provide the participants with the latest information available as presented at the 2021 American Society of Clinical Oncology (ASCO) meeting. Oncology/Hematology faculty members from the Indiana University School of Medicine will provide participants with analysis of the more clinically applicable presentations at this year's ASCO meeting.

Objectives:
At the end of this activity, participants should be able to:
• Recall and describe the newest developments in the treatment of breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, head/neck cancer, melanoma, hematological mallignancies.
• Integrate multimodality treatment strategies, including radiation therapy, chemotherapy, immunotherapy, and targeted therapy, into the management of patients with cancer.
• Based on the most up-to-date treatments described in the learning sessions, apply new knowledge and strategies about therapies of solid tumors and hematological malignancies into their clinical practice.